Signos Pricing History and Trajectory: Is It Worth the Cost?

What Is Signos and How Does Its Model Work?

Signos sells a monthly subscription that pairs an FDA-cleared CGM sensor with a proprietary mobile app. The app tracks postprandial glucose responses and delivers real-time nudges intended to reduce caloric intake and improve metabolic health. Subscribers receive CGM hardware, app access, and varying levels of coaching depending on the tier they choose.

The CGM Hardware Signos Uses

The sensors Signos ships are regulated medical devices. The Abbott FreeStyle Libre 3 and Dexcom G7 are both FDA-cleared as Class II devices for diabetes management, though neither is cleared specifically for weight loss in non-diabetic individuals. The FDA's device database confirms the FreeStyle Libre 3 clearance (K213332). The Dexcom G7 similarly holds 510(k) clearance for adjunctive use.

Using a diabetes-management device off-label for weight loss in metabolically healthy individuals is legal and common in the consumer wellness space. The FDA does not restrict physicians or consumers from using cleared devices in this manner. Still, off-label use means the specific weight-loss claim rests on the app's logic, not the sensor's clearance.

The App and Coaching Layer

Signos differentiates itself from simply buying a CGM retail through its algorithm, which assigns a personal glucose score and sends meal recommendations. Higher-tier plans add registered dietitian (RD) sessions. The coaching component is where the pricing spread between plans is most pronounced and also where most consumer complaints focus regarding perceived value.

Signos Pricing History: A Timeline

Signos has raised prices at least twice since launch. The trajectory matters because subscribers who auto-renew may be paying substantially more than they initially budgeted.

2020 to 2021: Launch Pricing

At launch in 2020, Signos offered a single plan around $199 per month billed monthly. Annual prepay brought the effective monthly cost to approximately $149. This was competitive with the retail cost of CGM sensors alone (a single FreeStyle Libre 14-day sensor retails for roughly $50 to $70 at launch, so the bundle commanded a meaningful premium for the software layer).

2022: First Significant Price Increase

By mid-2022, Signos restructured into tiered plans. The entry tier moved to approximately $249 per month. A premium tier with coaching sessions launched at approximately $349 per month. Consumer complaints on the Better Business Bureau and third-party review sites began appearing around this period, frequently citing the price jump and billing disputes.

2023 to 2024: Current Pricing Structure

The entry plan moved again, landing near $299 per month by late 2023. The premium tier reached approximately $399 per month. Annual billing options offer roughly 15 to 20 percent discounts, but members must pay upfront. A shorter two-month "starter" option appeared in 2024 at a slightly higher per-month rate than the annual plan.

The table below summarizes the pricing trajectory based on publicly available plan pages and archived pricing data.

| Period | Entry Plan (Monthly) | Premium Plan (Monthly) | Annual Discount | |---|---|---|---| | 2020 launch | ~$199 | N/A | ~$149/mo equiv. | | Mid-2022 | ~$249 | ~$349 | ~15% | | Late 2023 | ~$299 | ~$399 | ~15-20% | | Early 2025 | ~$299 | ~$399 | ~15-20% |

Why Prices Have Risen

Several structural factors drive Signos price increases. CGM sensor wholesale costs have not dropped as quickly as the company may have projected. Dexcom and Abbott control the CGM sensor supply chain, and both companies have signaled that consumer-wellness CGM demand is a new, premium market segment rather than a volume-discount category. Dexcom's 2023 annual report (10-K, SEC filing) explicitly identifies the "personal health" segment as a growth priority at maintained margins.

Platform build costs, RD staffing for coaching tiers, and marketing spend in a competitive GLP-1 and metabolic health market all add to overhead. Price increases in subscription wellness are common when a company transitions from growth-at-all-costs to unit-economics discipline.

The Clinical Evidence for CGM-Guided Weight Loss

The central question for any subscriber considering $299 to $399 per month is whether CGM feedback actually produces clinically meaningful weight loss. The answer is: possibly, in specific metabolic phenotypes, but the evidence is weaker than Signos marketing implies.

What the Research Actually Shows

A 2021 randomized controlled trial by Dempsey et al. Published in Obesity (N=23) tested real-time CGM feedback in adults with overweight or obesity and found modest improvements in dietary behavior, but the sample was too small to draw firm conclusions about weight outcomes. Dempsey PC et al., Obesity 2021.

The DIETFITS trial (N=609), published in JAMA in 2018, found that baseline insulin secretion phenotype predicted weight-loss response to low-fat versus low-carbohydrate diets. Gardner CD et al., JAMA 2018;319(7):667-679. This is indirectly relevant because Signos markets glucose-phenotype personalization as its core mechanism. However, DIETFITS did not use CGM and was not designed to test glucose-guided advice.

A 2022 review in The Lancet Diabetes and Endocrinology noted that CGM use in non-diabetic populations is growing faster than the evidence base. Ajjan RA et al., Lancet Diabetes Endocrinol 2022;10(6):386-392. The authors concluded that "evidence for CGM-guided lifestyle modification in metabolically healthy adults remains limited and should not be overstated."

Glucose Variability as a Weight-Loss Target

Signos's core hypothesis is that reducing postprandial glucose spikes (measured as glucose variability) leads to lower caloric intake and better weight outcomes. Some mechanistic support exists. A study in Cell Metabolism by Zeevi et al. (N=800) showed that glycemic responses to identical foods vary widely between individuals. Zeevi D et al., Cell 2015;163(5):1079-1094. This personalized nutrition concept underpins Signos's value proposition.

However, translating glycemic variability data into meaningful weight loss requires behavioral adherence to the app's recommendations. Adherence data from Signos's own platform has not been published in peer-reviewed literature as of early 2025.

GLP-1 Medications vs. CGM Subscriptions: A Practical Comparison

For context on value, the STEP-1 trial (N=1,961) showed semaglutide 2.4 mg produced 14.9 percent mean body weight loss at 68 weeks versus 2.4 percent with placebo (P<0.001). Wilding JPH et al., N Engl J Med 2021;384(11):989-1002. No CGM-based intervention has produced comparable weight-loss effect sizes in RCT data. Subscribers should weigh the $3,600 to $4,800 annual Signos cost against the clinical magnitude of available alternatives.

Is Signos Legit? Regulatory and Consumer Standing

"Legit" covers two distinct questions: is the company legally operating, and does the product deliver what it promises.

Legal and Regulatory Standing

Signos is a registered Delaware corporation operating as a direct-to-consumer telehealth-adjacent wellness platform. The CGM sensors it ships are FDA-cleared devices sold through authorized distribution channels. Signos itself is not an FDA-regulated manufacturer; it is a software and services company that fulfills sensor orders.

The FDA has issued guidance on digital health software functions and, in its 2022 Digital Health Center of Excellence policy framework, clarified that software offering general wellness advice (eating patterns, activity) is generally not subject to FDA regulation as a medical device. FDA Digital Health Center of Excellence, 2022. Signos operates under this general wellness software carve-out.

LegitScript, a third-party healthcare merchant verification service, does not currently list Signos in its certified pharmacy or telehealth directories. This is not disqualifying for a CGM software company (LegitScript primarily covers prescription dispensing), but it means Signos lacks that additional credentialing layer.

BBB Profile and Consumer Complaints

As of early 2025, the Better Business Bureau shows Signos is not accredited, with a pattern of complaints in two main categories: billing disputes (charges continuing after cancellation requests) and dissatisfaction with weight-loss results. BBB profile for Signos, bbb.org. Signos has responded to some complaints on the BBB platform.

Complaints about subscription wellness companies charging after cancellation are extremely common across the category, not unique to Signos. The FTC has ongoing enforcement actions against a range of subscription companies under its "negative option" rule amendments finalized in 2024. FTC Negative Option Rule, 16 CFR Part 425, 2024. Subscribers should document cancellation requests in writing via email and request written confirmation.

State Medical Board Considerations

Signos does not prescribe medications and does not employ physicians who make individual treatment decisions for subscribers in a traditional clinical relationship. The app's recommendations are algorithmic. This means state medical board jurisdiction is limited. The company's RD coaching sessions are governed by state dietitian licensing boards, which vary in their telehealth scope-of-practice rules.

Common Signos Complaints and What They Mean

Consumer review platforms (Trustpilot, Reddit, BBB) show a recognizable pattern of Signos-specific complaints worth addressing directly.

Complaint 1: Weight Loss Results Underwhelming

Many reviewers report losing little to no weight despite following app guidance. This matches the available clinical literature, which shows modest effect sizes for CGM-guided lifestyle intervention. A 2023 meta-analysis in Nutrients (N=7 studies, 342 participants) found that CGM use combined with dietary counseling reduced body weight by a mean of 1.8 kg versus control over 12 weeks. Maiorino MI et al., Nutrients 2023;15(3):564. At $300 per month, 1.8 kg over 12 weeks is a low return on investment for most subscribers.

Complaint 2: Difficulty Cancelling

Multiple BBB and Trustpilot reviews describe charges appearing after verbal or app-based cancellation attempts. Under the FTC's updated negative option rule, companies must provide a cancellation mechanism that is at least as easy as the signup mechanism and must honor requests promptly. FTC Negative Option Rule, 2024. Subscribers experiencing this issue can dispute charges with their credit card issuer under Regulation Z's billing error provisions and file complaints at ftc.gov/complaint.

Complaint 3: Sensor Gaps and Fulfillment Delays

CGM sensor fulfillment depends on supply chains outside Signos's direct control. Several reviewers report gaps of one to two weeks between sensor shipments, creating data gaps that reduce the app's feedback value. Signos's subscription pricing does not appear to prorate for fulfillment delays.

Complaint 4: Customer Service Response Times

Signos's support team is reachable via email and in-app messaging. Reviews on multiple platforms describe response times of 48 to 72 hours, which is slower than competitors in the CGM wellness space. This is a user experience issue rather than a safety concern, but it affects the overall value assessment.

How Signos Compares to Alternatives at Similar Price Points

At $299 to $399 per month, Signos competes directly with several other offerings.

Direct CGM Subscription Competitors

Levels Health, the most prominent direct competitor, operates at a comparable price point (approximately $199 to $299 per month depending on plan) and uses the same CGM hardware. Levels has published more content on its evidence base and has been cited in peer-reviewed commentary, though it similarly lacks a proprietary RCT. NutriSense is a third option at approximately $225 to $350 per month, adding RD support similar to Signos's premium tier.

All three platforms face the same fundamental evidentiary gap: no company has published a prospective RCT demonstrating that their app specifically produces superior weight outcomes versus a CGM-alone control group.

GLP-1 Telehealth Platforms

Compounded semaglutide and tirzepatide via telehealth platforms (Ro, Hims and Hers, HealthRX) typically range from $150 to $350 per month depending on dose and formulary. Given the STEP-1 trial's 14.9 percent weight-loss result at 68 weeks versus the 1.8 kg meta-analytic result for CGM-guided counseling, the pharmacological route offers substantially larger effect sizes for the same or lower monthly spend. Wilding JPH et al., N Engl J Med 2021;384(11):989-1002.

The populations are not identical. GLP-1 agonists carry side-effect profiles and require prescriber oversight. CGM subscriptions are appropriate for individuals who are not GLP-1 candidates, prefer non-pharmacological approaches, or want metabolic data alongside a medication regimen.

Using CGM Alongside GLP-1 Therapy

A 2023 observational study in Diabetes Care (N=154) found that patients using CGM alongside GLP-1 receptor agonist therapy showed greater time-in-range improvement than GLP-1 therapy alone, suggesting a potential complementary role. Battelino T et al., Diabetes Care 2023;46(2):e1-e4. A Signos subscription on top of a GLP-1 regimen is one possible use case where the CGM data layer might add marginal value, though the incremental benefit above simply wearing a retail CGM sensor is unquantified.

Who Should (and Should Not) Consider Signos

Potentially Appropriate Candidates

Adults with prediabetes or insulin resistance (fasting glucose 100 to 125 mg/dL, per ADA criteria) represent the population most likely to benefit from glucose-guided dietary feedback. American Diabetes Association Standards of Care 2024, Section 3. In this group, postprandial glucose management has direct clinical relevance beyond weight loss.

Individuals who have tried calorie-counting apps without success and have a specific interest in glycemic data may find the feedback loop motivating. Behavioral adherence is the limiting factor, as it is with any dietary intervention.

Populations Who Should Look Elsewhere

Individuals with BMI above 30 kg/m2 with comorbidities (hypertension, dyslipidemia, type 2 diabetes) should discuss GLP-1 receptor agonist therapy with a clinician before committing $3,600 or more annually to a CGM subscription. The 2023 American Gastroenterological Association clinical practice guideline recommends pharmacotherapy as first-line adjunct to lifestyle intervention in adults with BMI <30 with weight-related comorbidities, and as first-line in BMI above 30. Camilleri M et al., Gastroenterology 2022;163(5):1198-1225.

Individuals with a history of eating disorders should exercise caution with any system that assigns scores to food choices and monitors postprandial responses in real time, as this feedback structure may reinforce disordered patterns. Neumark-Sztainer D et al., J Adolesc Health 2018;63(5):523-529.

Practical Guidance Before Subscribing

Before entering a Signos subscription, prospective members should take four concrete steps.

First, request a copy of Signos's cancellation policy in writing via their support email before subscribing. Save the response. This creates a paper trail if billing disputes arise.

Second, check whether your health insurance or FSA/HSA plan covers CGM devices for non-diabetic metabolic monitoring. The IRS has not issued a blanket ruling on CGM expenses for non-diabetic individuals under FSA/HSA eligibility, though individual plan administrators may approve them. IRS Publication 502, Medical and Dental Expenses. Some subscribers have successfully submitted CGM costs as qualified medical expenses with a letter of medical necessity from a physician.

Third, compare the entry-tier Signos plan against purchasing a FreeStyle Libre 3 sensor directly (approximately $50 to $70 per sensor, two sensors per month at standard wear time) plus a free glucose-tracking app such as Glucose Buddy. The software layer is where Signos's premium sits, and that value is genuinely subjective.

Fourth, if your primary goal is weight loss greater than 10 percent of body weight, schedule a telehealth visit with a physician to discuss FDA-approved pharmacotherapy. The evidence gap between CGM-guided lifestyle intervention and GLP-1 therapy is large and well-documented in peer-reviewed literature.